

# Simon L Parsons

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11999484/publications.pdf>

Version: 2024-02-01

15  
papers

2,086  
citations

840776

11  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

2470  
citing authors

#	ARTICLE	IF	CITATIONS
1	The management and long-term outcomes of endoscopic and surgical treatment of early esophageal adenocarcinoma. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.4	3
2	A systematic review of patient reported outcome measures (PROMs) and quality of life reporting in patients undergoing laparoscopic cholecystectomy. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 228-245.	1.5	14
3	Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 85-92.	1.3	5
4	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. <i>Gastroenterology</i> , 2018, 155, 1720-1728.e4.	1.3	67
5	The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. <i>Journal of Surgical Oncology</i> , 2017, 115, 821-829.	1.7	30
6	Individual patient oesophageal cancer 3D models for tailored treatment. <i>Oncotarget</i> , 2017, 8, 24224-24236.	1.8	12
7	Development of a telehealth monitoring service after colorectal surgery: A feasibility study. <i>World Journal of Gastrointestinal Surgery</i> , 2017, 9, 193-199.	1.5	16
8	3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 753-763.	4.1	30
9	The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study. <i>Clinical Cancer Research</i> , 2014, 20, 3348-3357.	7.0	17
10	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , 2014, 63, 7-42.	12.1	1,116
11	Oesophago-Gastric Cancer. , 2012, , 221-244.		9
12	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. <i>International Journal of Cancer</i> , 2010, 127, 2209-2221.	5.1	464
13	Novel staining pattern of p53 in Barrett's dysplasia - the absent pattern. <i>Histopathology</i> , 2010, 57, 933-935.	2.9	47
14	Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. <i>Histopathology</i> , 2009, 54, 699-712.	2.9	164
15	Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. <i>European Journal of Surgical Oncology</i> , 1997, 23, 526-531.	1.0	92